Venetoclax with azacytidine for newly diagnosed T-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 14 years old.
- You must have newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) with certain genetic changes or a mixed leukemia type.
- You cannot have had any prior strong chemotherapy, though limited treatments like low-dose medications or leukapheresis are okay.
- Your major organs (liver, kidneys, heart) must be working well enough based on blood tests and heart scan.
- You must not be pregnant, breastfeeding, or unwilling to use contraception if of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
This trial tests a combination of drugs for people newly diagnosed with a rare and aggressive type of T-cell acute lymphoblastic leukemia (ETP-ALL). The goal is to see if this combination can help put the leukemia into remission.
This Phase 2 study tests whether venetoclax combined with azacitidine can help people with ALAL (an “ambiguous” type of acute leukemia). It also checks whether the combination is safe for newly diagnosed patients with adequate heart, liver, and kidney health.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hear when a new T Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.